Ottobre 2005 - Volume XXIV - numero 8

Medico e Bambino


Ricerca

Le priorità associate all’uso dei farmaci “off-label”

F. MARCHETTI1, J. BUA1, S. DEMARINI1, R. DEVESCOVI1, C. GERMANI1, P. MERGONI1, G. MESSI1, M. PENNESI1, M. RABUSIN1, A. SARTI1, A. VENTURA1; A. ARRIGHINI2, G. CHIRICO2, M. DUSE2, N. MIGLIETTI2, M.S. MOLINARO2, L.D. NOTARANGELO2, F. PORTA2, V. PORTERI2, E. SONCINI2, R.F. SCHUMACHER2; S. DI MAIO3, L. DI MARTINO3, L. GIORDANO3, F. DE LEVA3, C. PECORARO3; M. BALDI4, E. BANAUDI4, S. EINAUDI4, G. MIGLIORE4, P. PECCO4, P. SARACCO4, A. TOCCHET4; M. BONATI5

1Istituto per l'Infanzia “Burlo Garofolo”, Trieste (coordinamento);
2Ospedale dei Bambini, Brescia;
3AO Santobono - Pausilipon, Napoli;
4AO OIRM S. Anna, Torino;
5Laboratorio per la Salute Materno-Infantile, Istituto Mario Negri, Milano

Indirizzo per corrispondenza: marchetti@burlo.trieste.

PRIORITIES AMONG OFF-LABEL PRESCRIPTIONS: PAEDIATRICIANS’ PERSPECTIVE

Key words: Off-label drugs, Children, Hospital-based survey

Two thirds of the drugs prescribed for children are off-label. However, off-label is not synonymous with incorrect, since it often represents the most rational, evidence-based therapy. Existing data on the use of off-label in children are based on prescriptions registers. The aim of our study was to investigate the paediatricians’ perspective on off-label use in their everyday hospital practice. Four Paediatrics Italian Hospitals were involved in the study. Questionnaires covered eight different department/speciality units. Our findings showed that the most common reasons detected for off-label use were formulation and age. Corticosteroids, antihypertensive drugs and midazolam were most frequently indicated as off-label for formulation, while ciprofloxacin, new generation anti-epilepsy drugs (lamotrigine, oxcarbazepine) and immunosuppressant (mycophenolate, rituximab) for age. The drugs identified as off-label differed according to department, although some recurred (i.e. ACE inhibitors, ketorolac). Our survey might be of help for planning appropriate interventions to tackle the problem of off-label use in paediatrics.

Vuoi citare questo contributo?

F. Marchetti, J. Bua, S. Demarini, et al.
Le priorità associate all’uso dei farmaci “off-label”
Medico e Bambino 2005;24(8):527-531 https://www.medicoebambino.com/?id=0508_527.pdf


leggi l'articolo in formato PDF